Genetic Factors Affecting Schizophrenia Treatment Response
Author Information
Author(s): Sami Anttila, Olli Kampman, Ari Illi, Riikka Rontu, Terho Lehtimäki, Esa Leinonen
Primary Institution: University of Tampere, Medical School
Hypothesis
Functional SNPs would alter serotonergic neurotransmission and stress response in the CNS, potentially influencing treatment response in schizophrenia.
Conclusion
The study suggests that serotonergic mechanisms may significantly impact medication response in schizophrenia, highlighting the need for further research.
Supporting Evidence
- The study found a significant association between the 5-HT2A T102C polymorphism and treatment response in female patients.
- TPH1 A779C genotype was inversely associated with good treatment response.
- GNB3 C825T genotype showed a trend towards better response in male patients.
Takeaway
This study looked at how certain genes might affect how well people with schizophrenia respond to their medications. It found that some genetic differences could help explain why some people do better with treatment than others.
Methodology
The study involved 94 schizophrenia patients and 392 healthy controls, analyzing genetic polymorphisms related to serotonergic neurotransmission.
Potential Biases
Selection criteria for patient subgroups may introduce bias in treatment response comparisons.
Limitations
The small sample size, especially in gender comparisons, may limit the generalizability of the findings.
Participant Demographics
94 schizophrenia patients (43 responders, 51 non-responders) and 392 healthy controls, with a mix of genders.
Statistical Information
P-Value
0.005
Confidence Interval
95% CI 1.46–21.93
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website